Re: Resverlogix Announces Corporate Update Conference Call ... Bear
in response to
by
posted on
Jun 07, 2020 01:31PM
Actually it's only page 200 of the entire doc and it concludes the following :
3P-MACE + Hosp CHF, baseline eGFR <60 ml/min with a P-Value = 0.02.
"Conclusion: Patients with T2D, ACS, and Stage 3 CKD have a very high risk of subse-quent MACE plus CHF hospitalization. The BET protein inhibitor ABP may reduce this risk."
That's all I see.
Koo